Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vertex Pharmaceutic 50 NORTHERN AVENUE BOSTON MA 02210 USA

P: 617-341-6100

Description:

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

Key Statistics

Overview:

Market Capitalization, $K 69,268,952
Shares Outstanding, K 255,756
Annual Sales, $ 7,574 M
Annual Net Income, $ 2,342 M
Last Quarter Sales, $ 2,098 M
Last Quarter Net Income, $ 762,100 K
60-Month Beta 0.55
% of Insider Shareholders 0.40%
% of Institutional Shareholders 89.84%
Float, K 254,733
% Float 99.60%
Short Volume Ratio 0.27

Growth:

1-Year Return 30.39%
3-Year Return 62.26%
5-Year Return 107.58%
5-Year Revenue Growth 344.98%
5-Year Earnings Growth 10,890.91%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 3.52 on 05/05/22
Next Earnings Date N/A
Earnings Per Share ttm 12.39
EPS Growth vs. Prev Qtr -0.63%
EPS Growth vs. Prev Year 24.41%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 08/24/00

VRTX Ratios

Ratio
Price/Earnings ttm 21.67
Price/Earnings forward 21.54
Price/Earnings to Growth 1.98
Return-on-Equity % 32.24%
Return-on-Assets % 24.39%
Profit Margin % 30.92
Net Margin % -266.58
Debt/Equity 0.05
Price/Sales 9.07
Price/Cash Flow 21.25
Price/Book 6.30
Book Value/Share 42.65
Interest Coverage 45.40
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar